Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight

News provided by

28 Jan, 2025, 22:31 GMT

DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence of numerous therapies in the pipeline set to launch within the forecast period.

LAS VEGAS, Jan. 28, 2025 /PRNewswire/ -- DelveInsight's Dry Eye Disease Market Insights report includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Takeaways from the Dry Eye Disease Market Report

According to DelveInsight's analysis, the market size for dry eye disease was found to be USD 3.7 billion in the 7MM in 2023.
The United States accounted for the highest market size of DED ~73% of the total market size in 7MM in 2023, in comparison to the other major markets i.e., EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54.6 million in 2023.
Leading dry eye disease companies such as Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis, and others are developing novel dry eye disease drugs that can be available in the dry eye disease market in the coming years.
The promising dry eye disease therapies in the pipeline include PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others.

Discover which therapies are expected to grab the major dry eye disease market share @ Dry Eye Disease Market Report

Dry Eye Disease Overview

Dry eye disease (DED) is a common chronic condition characterized by inadequate tear production or excessive tear evaporation, leading to inflammation and damage to the eye's surface. Causes of DED are multifactorial and include aging, hormonal changes, prolonged screen use, environmental factors (dry climates, wind), certain medications, autoimmune conditions, and contact lens wear. Symptoms often include persistent dryness, redness, irritation, a gritty or sandy sensation, sensitivity to light, blurry vision, and in some cases, paradoxical excessive tearing.

Diagnosing DED typically involves a thorough eye examination by an ophthalmologist or optometrist. Common diagnostic tests include the Schirmer test, tear breakup time, and ocular surface staining with dyes such as fluorescein or lissamine green to detect surface damage. Early diagnosis and management are essential to prevent complications like corneal damage and vision impairment.

Dry Eye Disease Epidemiology Segmentation

The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The dry eye disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases
Gender-specific Diagnosed Prevalent Cases
Age-specific Diagnosed Prevalent Cases
Severity-specific Diagnosed Prevalent Cases

Dry Eye Disease Treatment Market

Pharmacological treatments play a pivotal role in the comprehensive management of dry eye disease. Common solutions like artificial tears provide quick relief by enhancing the tear film, while prescription medications such as cyclosporine (e.g., RESTASIS) and lifitegrast (e.g., XIIDRA) help alleviate symptoms through their anti-inflammatory effects. Recently approved therapies, including VEVYE (cyclosporine ophthalmic solution)/CyclASol and MIEBO (NOV03), offer new and promising options.

Beyond pharmacological approaches, other strategies for managing DED include in-office treatments like intense pulsed light therapy and meibomian gland expression, as well as eyelid care techniques such as warm compresses and lid scrubs. For more severe cases, lifestyle changes, punctal plugs, or scleral contact lenses may be considered to provide additional symptom relief.

The eye drop market is largely focused on alleviating dry eye symptoms using moisturizing agents such as hyaluronic acid. However, there is a notable gap in effective treatments for viral keratoconjunctivitis, a condition often mismanaged with antibiotics. Marinomed Biotech AG's MAM-1001-3 eye drops aim to address this need by leveraging Carragelose, a red seaweed-derived polymer with exceptional moisturizing and broad-spectrum antiviral properties.

Classified as a medical device and in the pre-launch phase with MDD certification, MAM-1001-3 provides dual benefits: soothing dry, irritated eyes and potentially offering a targeted solution for viral keratoconjunctivitis, thereby advancing patient care in ocular health. In summary, implementing a personalized combination of these management strategies can effectively reduce symptoms and enhance the quality of life for individuals with DED.

To know more about dry eye disease treatment guidelines, visit @ Dry Eye Disease Management

Dry Eye Disease Pipeline Therapies and Key Companies

PL9643: Palatin Technologies, Inc.
Reproxalap: Aldeyra Therapeutics, Inc.
RGN-259 (Tß4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.
Tavilermide (MIM-D3): Mimetogen
AR-15512: Alcon/Aerie Pharmaceuticals
BRM421: BRIM Biotechnology, Inc.
SI-614: Seikagaku Corporation
SkQ1 eye drops: Mitotech
SJP-0132: Senju Pharmaceutical
Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar
ST-100 (Vezocolmitide): Stuart Therapeutics
VVN001: VivaVision Biotech
Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.
RP101: Redwood Pharma AB
AXR-270 (cream): AxeroVision, Inc.
OK-101: OKYO Pharma
AXR-270: AxeroVision, Inc.
AXR-159: AxeroVision, Inc.
GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation
Licaminlimab (OCS-02): Oculis

Discover more about dry eye disease drugs in development @ Dry Eye Disease Clinical Trials

Dry Eye Disease Market Dynamics

The dry eye disease market dynamics are expected to change in the coming years. Dry eye is a highly prevalent condition, especially among the aging population, creating a substantial need for effective diagnosis, treatment, and management solutions. Current treatment options, such as artificial tears, prescription drugs, eyelid hygiene products, and punctal plugs, enable tailored approaches to address the condition. Increased public education campaigns can raise awareness and encourage individuals to seek help, while collaboration among pharmaceutical companies, research institutions, and healthcare providers can drive the development of novel therapies and diagnostic tools for dry eye disease.

Furthermore, potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the dry eye disease market in the 7MM.

However, several factors may impede the growth of the dry eye disease market. Some dry eye treatments, particularly prescription medications, can cause side effects like blurred vision or itching, while the cost of treatment, including medications and frequent healthcare visits, can be burdensome for patients; additionally, intense market competition increases pricing pressures and marketing expenditures for companies, and failure to properly diagnose or treat dry eye may lead to disease progression and complications, significantly impacting patient health and well-being.

Moreover, dry eye disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, dry eye disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact dry eye disease market growth.

Dry Eye Disease Market Report Metrics	Details
Study Period	2020–2034
Coverage	7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Dry Eye Disease Market Size in 2023	USD 3.7 Billion
Key Dry Eye Disease Companies	Palatin Technologies, Inc., Aldeyra Therapeutics, Inc., ReGenTree, RegeneRx Biopharmaceuticals, Inc., Mimetogen, Alcon, Aerie Pharmaceuticals, BRIM Biotechnology, Inc., Seikagaku Corporation, Mitotech, Senju Pharmaceutical, Sylentis, S.A., PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll BioPharma Co., Ltd., Daewoong Pharmaceutical Co. Ltd., Redwood Pharma AB, OKYO Pharma, AxeroVision, Inc., Glaukos Corporation, Oculis, and others
Key Pipeline Dry Eye Disease Therapies	PL9643, Reproxalap, RGN-259 (Tß4), Tavilermide (MIM-D3), AR-15512, BRM421, SI-614, SkQ1 eye drops, SJP-0132, Tivanisiran (SYL1001), ST-100 (Vezocolmitide), VVN001, Tanfanercept Ophthalmic Solution/HL036, RP101, AXR-270 (cream), OK-101, AXR-270, AXR-159, GLK-301 (Pilocarpine Ophthalmic Topical Cream), Licaminlimab (OCS-02), and others

Scope of the Dry Eye Disease Market Report

Therapeutic Assessment: Dry Eye Disease current marketed and emerging therapies
Dry Eye Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Dry Eye Disease Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Dry Eye Disease Market Access and Reimbursement

Download the report to understand which factors are driving dry eye disease market trends @ Dry Eye Disease Market Trends

Table of Contents

1	Key Insights
2	Report Introduction
3	Dry Eye Disease (DED) Market Overview at a Glance
3.1	Market Share (%) Distribution by Therapies of DED in 2020
3.2	Market Share (%) Distribution by Therapies of DED in 2034
4	Epidemiology and Market Methodology of DED
5	Executive Summary of Dry Eye Disease (DED)
6	Key Events
7	Disease Background and Overview
7.1	Introduction
7.2	Tear Film Working
7.3	Etiology
7.4	Risk Factors
7.5	Pathophysiology
7.6	Symptoms and Clinical Presentations
7.7	Diagnosis
7.7.1	Diagnostic Criteria
7.7.1.1	Comparison of Dry Eye Definition and Diagnostic Criteria between JDES/ADES and DEWS II
7.7.1.2	Diagnostic Criteria of the JDES, 1995 Version
7.7.1.3	Diagnostic criteria of DED proposed by the JDES (2006 version)
7.7.2	Differential Diagnosis
7.7.3	Diagnostic Algorithm
7.7.4	Diagnostic Scheme
7.7.5	Diagnostic Guidelines
7.7.5.1	Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology
7.8	Treatment and Management
7.8.1	Treatment Algorithm
7.8.2	Treatment Guidelines
7.8.2.1	TFOS DEWS II Management and Therapy Guidelines
7.8.2.2	Dry Eye Syndrome Preferred Practice Pattern guidelines by American Academy of Ophthalmology
8	Epidemiology and Patient Population
8.1	Key Findings
8.2	Assumptions and Rationale: The 7MM
8.2.1	Diagnosed Prevalence of DED
8.2.2	Gender-specific Prevalence of DED
8.2.3	Age-specific Diagnosed Prevalence of DED
8.2.4	Severity-specific Diagnosed Prevalence of DED
8.3	Total Diagnosed Prevalent Cases of DED in the 7MM
8.4	The United States
8.4.1	Total Diagnosed Prevalent Cases of DED
8.4.2	Gender-specific Diagnosed Prevalent Cases of DED
8.4.3	Age-specific Diagnosed Prevalent Cases of DED
8.4.4	Severity-specific Diagnosed Prevalent Cases of DED
8.5	EU4 and the UK
8.5.1	Germany
8.5.1.1	Total Diagnosed Prevalent Cases of DED in Germany in Germany
8.5.1.2	Gender-specific Diagnosed Prevalent Cases of DED in Germany
8.5.1.3	Age-specific Diagnosed Prevalent Cases of DED in Germany
8.5.1.4	Severity-specific Diagnosed Prevalent Cases of DED in Germany
8.5.2	France
8.5.2.1	Total Diagnosed Prevalent Cases of DED in France
8.5.2.2	Gender-specific Diagnosed Prevalent Cases of DED in France
8.5.2.3	Age-specific Diagnosed Prevalent Cases of DED in France
8.5.2.4	Severity-specific Diagnosed Prevalent Cases of DED in France
8.5.3	Italy
8.5.3.1	Total Diagnosed Prevalent Cases of DED in Italy
8.5.3.2	Gender-specific Diagnosed Prevalent Cases of DED in Italy
8.5.3.3	Age-specific Diagnosed Prevalent Cases of DED in Italy
8.5.3.4	Severity-specific Diagnosed Prevalent Cases of DED in Italy
8.5.4	Spain
8.5.4.1	Total Diagnosed Prevalent Cases of DED in Spain
8.5.4.2	Gender-specific Diagnosed Prevalent Cases of DED in Spain
8.5.4.3	Age-specific Diagnosed Prevalent Cases of DED in Spain
8.5.4.4	Severity-specific Diagnosed Prevalent Cases of DED in Spain
8.5.5	The United Kingdom
8.5.5.1	Total Diagnosed Prevalent Cases of DED in the UK
8.5.5.2	Gender-specific Diagnosed Prevalent Cases of DED in the UK
8.5.5.3	Age-specific Diagnosed Prevalent Cases of DED in the UK
8.5.5.4	Severity-specific Diagnosed Prevalent Cases of DED in the UK
8.6	Japan
8.6.1	Total Diagnosed Prevalent Cases of DED
8.6.2	Gender-specific Diagnosed Prevalent Cases of DED
8.6.3	Age-specific Diagnosed Prevalent Cases of DED in the US
8.6.4	Severity-specific Diagnosed Prevalent Cases of DED
9	Patient Journey
10	Marketed Therapies
10.1	Key Cross Competition of Marketed Therapies
10.2	CEQUA (cyclosporine ophthalmic solution) 0.09%: Sun Pharm
10.2.1	Product Description
10.2.2	Regulatory Approval
10.2.3	Other Developmental Activities
10.2.4	Clinical Development
10.2.5	Clinical Trials Information
10.2.6	Safety and Efficacy
10.2.7	Product Profile
10.3	TYRVAYA (varenicline solution): OYSTER POINT PHARMA
10.3.1	Product Description
10.3.2	Regulatory Approval
10.3.3	Other Developmental Activities
10.3.4	Clinical Development
10.3.5	Clinical Trials Information
10.3.6	Safety and Efficacy
10.3.7	Product Profile
10.4	EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%: ALCON LABS INC/Kala Pharmaceuticals
10.4.1	Product Description
10.4.2	Regulatory Approvals
10.4.3	Other Developmental Activities
10.4.4	Clinical Development
10.4.5	Clinical Trials Information
10.4.6	Safety and Efficacy
10.4.7	Product Profile
10.5	VEVYE (cyclosporine ophthalmic solution)/ CyclASol: Novaliq/ Harrow Eye
10.5.1	Product Description
10.5.2	Regulatory Approvals
10.5.3	Other Developmental Activities
10.5.4	Clinical Development
10.5.5	Clinical Trials Information
10.5.6	Safety and Efficacy
10.5.7	Product Profile
10.6	MIEBO (NOV03): Bausch & Lomb Incorporated/Novaliq
10.6.1	Product Description
10.6.2	Regulatory Approval
10.6.3	Other Developmental Activities
10.6.4	Clinical Development
10.6.5	Clinical Trials Information
10.6.6	Safety and Efficacy
10.6.7	Product Profile
11	Emerging Therapies
11.1	Key Cross Competition of Emerging Therapies
11.2	PL9643: Palatin Technologies, Inc.
11.2.1	Product Description
11.2.2	Other Developmental Activities
11.2.3	Clinical Development
11.2.4	Clinical Trials Information
11.2.5	Safety and Efficacy
11.2.6	Product Profile
11.2.7	Analyst View
11.3	Reproxalap: Aldeyra Therapeutics, Inc.
11.3.1	Product Description
11.3.2	Other Developmental Activities
11.3.3	Clinical Development
11.3.4	Clinical Trials Information
11.3.5	Safety and Efficacy
11.3.6	Product Profile
11.3.7	Analyst Views
11.4	RGN-259 (Tβ4): ReGenTree/RegeneRx Biopharmaceuticals, Inc.
11.4.1	Product Description
11.4.2	Other Developmental Activities
11.4.3	Clinical Development
11.4.4	Clinical Trials Information
11.4.5	Safety and Efficacy
11.4.6	Product Profile
11.4.7	Analyst Views
11.5	Tavilermide (MIM-D3): Mimetogen
11.5.1	Product Description
11.5.2	Other Developmental Activities
11.5.3	Clinical Development
11.5.4	Clinical Trials Information
11.5.5	Safety and Efficacy
11.5.6	Product Profile
11.5.7	Analyst Views
11.6	AR-15512: Alcon/Aerie Pharmaceuticals
11.6.1	Product Profile
11.6.2	Other Developmental Activities
11.6.3	Clinical Development
11.6.4	Clinical Trials Information
11.6.5	Safety and Efficacy
11.6.6	Product Profile
11.6.7	Analyst Views
11.7	BRM421: BRIM Biotechnology, Inc.
11.7.1	Product Description
11.7.2	Other Developmental Activities
11.7.3	Clinical Development
11.7.4	Clinical Trials Information
11.7.5	Safety and Efficacy
11.7.6	Product Profile
11.7.7	Analyst Views
11.8	SI-614: Seikagaku Corporation
11.8.1	Product Description
11.8.2	Other Developmental Activities
11.8.3	Clinical Development
11.8.4	Clinical Trials Information
11.8.5	Product Profile
11.8.6	Analyst Views
11.9	SkQ1 eye drops: Mitotech
11.9.1	Product Description
11.9.2	Other Developmental Activities
11.9.3	Clinical Development
11.9.4	Clinical Trials Information
11.9.5	Safety and Efficacy
11.9.6	Product Profile
11.9.7	Analysts' Views
11.10	SJP-0132: Senju Pharmaceutical
11.10.1	Product Description
11.10.2	Other Developmental Activities
11.10.3	Clinical Development
11.10.4	Clinical Trials Information
11.10.5	Safety and Efficacy
11.10.6	Product Profile
11.10.7	Analysts' Views
11.11	Tivanisiran (SYL1001): Sylentis, S.A./PharmaMar
11.11.1	Product Description
11.11.2	Other Developmental Activities
11.11.3	Clinical Development
11.11.4	Clinical Trials Information
11.11.5	Safety and Efficacy
11.11.6	Product Profile
11.11.7	Analysts' Views
11.12	ST-100 (Vezocolmitide): Stuart Therapeutics
11.12.1	Product Description
11.12.2	Other Developmental Activities
11.12.3	Clinical Development
11.12.4	Clinical Trials Information
11.12.5	Safety and Efficacy
11.12.6	Product Profile
11.12.7	Analysts' Views
11.13	VVN001: VivaVision Biotech
11.13.1	Product Description
11.13.2	Other Developmental Activities
11.13.3	Clinical Development
11.13.4	Clinical Trials Information
11.13.5	Safety and Efficacy
11.13.6	Product Profile
11.13.7	Analysts' Views
11.14	Tanfanercept Ophthalmic Solution/HL036: HanAll BioPharma Co., Ltd./Daewoong Pharmaceutical Co. Ltd.
11.14.1	Product Description
11.14.2	Other Developmental Activities
11.14.3	Clinical Development
11.14.4	Clinical Trials Information
11.14.5	Safety and Efficacy
11.14.6	Product Profile
11.14.7	Analysts' Views
11.15	RP101: Redwood Pharma AB
11.15.1	Product Description
11.15.2	Other Developmental Activities
11.15.3	Clinical Development
11.15.4	Clinical Trials Information
11.15.5	Safety and Efficacy
11.15.6	Product Profile
11.15.7	Analysts' Views
11.16	AXR-270 (cream): AxeroVision, Inc.
11.16.1	Product Description
11.16.2	Clinical Development
11.16.3	Clinical Trials Information
11.16.4	Safety and Efficacy
11.16.5	Product Profile
11.16.6	Analyst Views
11.17	OK-101: OKYO Pharma
11.17.1	Product Description
11.17.2	Other Developmental Activities
11.17.3	Clinical Development
11.17.4	Clinical Trials Information
11.17.5	Safety and Efficacy
11.17.6	Product Profile
11.17.7	Analyst Views
11.18	AXR-270: AxeroVision, Inc.
11.18.1	Product Description
11.18.2	Other Developmental Activities
11.18.3	Clinical Development
11.18.4	Clinical Trials Information
11.18.5	Safety and Efficacy
11.18.6	Product Profile
11.18.7	Analyst Views
11.19	AXR-159: AxeroVision, Inc.
11.19.1	Product Description
11.19.2	Other Developmental Activities
11.19.3	Clinical Development
11.19.4	Clinical Trials Information
11.19.5	Safety and Efficacy
11.19.6	Product Profile
11.19.7	Analyst Views
11.20	GLK-301 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation
11.20.1	Product Description
11.20.2	Other Developmental Activities
11.20.3	Clinical Development
11.20.4	Clinical Trials Information
11.20.5	Safety and Efficacy
11.20.6	Product Profile
11.20.7	Analyst Views
11.21	Licaminlimab (OCS-02): Oculis
11.21.1	Product Description
11.21.2	Other Developmental Activities
11.21.3	Clinical Development
11.21.4	Clinical Trials Information
11.21.5	Safety and Efficacy
11.21.6	Product Profile
11.21.7	Analyst Views
12	DED: Market Analysis
12.1	Key Findings
12.2	Key Market Forecast Assumptions
12.3	Market Outlook
12.4	Conjoint Analysis
12.5	Total Market Size of DED in the 7MM
12.6	Market Size of DED by Therapies in the 7MM
12.7	Market Size of DED in the United States
12.7.1	Total Market Size of DED in the United States
12.7.2	Market Size of DED by Therapies
12.8	Market Size of DED in EU4 and the UK
12.8.1	Germany
12.8.1.1	Total Market Size of DED
12.8.1.2	Market Size of DED by Therapies
12.8.2	France
12.8.2.1	Total Market Size of DED
12.8.2.2	Market Size of DED by Therapies
12.8.3	Italy
12.8.3.1	Total Market Size of DED
12.8.3.2	Market Size of DED by Therapies
12.8.4	Spain
12.8.4.1	Total Market Size of DED
12.8.4.2	Market Size of DED by Therapies
12.8.5	The United Kingdom
12.8.5.1	Total Market Size of DED
12.8.5.2	Market Size of DED by Therapies
12.9	Market Size of DED in Japan
12.9.1	Total Market Size of DED
12.9.2	Market Size of DED by Therapies in Japan
13	Key Opinion Leaders' Views
14	SWOT Analysis
15	Unmet Needs
16	Market Access and Reimbursement
16.1	The United States
16.1.1	Center for Medicare and Medicaid Services (CMS)
16.2	In EU4 and the UK
16.2.1	Germany
16.2.2	France
16.2.3	Italy
16.2.4	Spain
16.2.5	The United Kingdom
16.3	Japan
16.3.1	MHLW
17	Appendix
17.1	Bibliography
17.2	Acronyms and Abbreviations
17.3	Report Methodology
18	DelveInsight Capabilities
19	Disclaimer

Dry Eye Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the dry eye disease epidemiology trends.

Dry Eye Disease Pipeline

Dry Eye Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dry eye disease companies, including Alcon, Seikagaku Corporation, Huons, Aramis Biosciences, Invirsa, Inc., IVIEW Therapeutics, Seinda Pharmaceutical, Serentrix, EyeD Pharma, SELAGINE, Theratome Bio, Alchemedicine, among others.

Glaucoma Market

Glaucoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others.

Glaucoma Pipeline

Glaucoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glaucoma companies, including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision, HK inno.N, Avirmax Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg